High
sensitivity and specificity of targeted MR/Ultrasound fusion biopsy in
delineating prostate lesions compared to other traditional technologies such as
TRUS biopsy, PSA test, or Digital Rectal Examination is expected to contribute
to the market growth. The reliability and reproducibility of the fusion biopsy
system in the diagnosis of aggressive tumors is expected to make it a standard
tool in prostate biopsy.
An
increasing number of radiologists gaining expertise in interpreting prostate
MRI coupled with the implementation of standard image grading systems such as
PI-RADS and Gleason score has increased the utilization rate of targeted
MR/Ultrasound fusion biopsy systems.
The
increasing number of government initiatives in terms of funding research,
spreading awareness, and conducting mass screening programs related to prostate
cancer are expected to play a crucial in the growth of the market. Some of the
growth strategies adopted by market players include partnership, product
launch, participation in trade events and conferences, and acquisitions to
sustain in this highly competitive market.
Related Press
Release@ Fusion
Biopsy Market Report
Fusion Biopsy Market Report Highlights
- The
transrectal segment held the largest market share in 2019, as it is the
gold standard and commonly used method of prostate fusion biopsy
- The
transperineal segment is expected to grow at the fastest rate during the
forecast period owing to the safety, diagnostic efficiency, and ability to
access the ventral prostate areas
- The hospital
segment accounted for the largest revenue share in 2019 because of the
factors such as increasing the procurement rate of MR/US targeted fusion
biopsy systems in teaching hospitals
- The
diagnostics centers segment is expected to grow at a significant rate over
the forecast period. Shorter wait times, cost efficiency, and developing
reimbursement paradigm are the factors expected to drive the growth of
this segment
- North
America held the largest market share in the market in 2019 and is
anticipated to maintain its dominance over the forecast period
- Asia Pacific
is anticipated to witness a CAGR of 10.5% during the forecast period owing
to factors such as growing awareness about the sensitivity and specificity
of MRI/US targeted fusion biopsy systems among urologists especially in
countries such as Japan, Australia, and China.
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment